Forecast
Period
|
2026-2030
|
Market
Size (2024)
|
USD 94.60 Billion
|
Market
Size (2030)
|
USD 101.56 Billion
|
CAGR
(2025-2030)
|
1.15%
|
Fastest
Growing Segment
|
Viral
Vaccine
|
Largest
Market
|
North
America
|
Market Overview
Global Respiratory Disease Vaccine Market was
valued at USD 94.60 Billion in 2024 and is anticipated to witness an impressive
growth in the forecast period with a CAGR of 1.15% through 2030. Respiratory diseases, also known as
respiratory disorders or lung diseases, encompass a broad category of medical
conditions that affect the respiratory system. An estimated 2 billion individuals are subjected to the harmful impacts of biomass fuel consumption, while 1 billion face exposure to outdoor air pollution, and another 1 billion are affected by tobacco smoke. These environmental and lifestyle factors contribute to the premature death of approximately 4 million people annually due to chronic respiratory diseases. The respiratory system includes
the organs and structures responsible for breathing, oxygen exchange, and
carbon dioxide removal. The primary organs involved in the respiratory system
are the lungs, but other components, such as the airways and muscles, also play
crucial roles. Respiratory diseases can be caused by various infectious agents,
including bacteria, viruses, and fungi. In addition to the flu and pneumonia,
other respiratory infections include bronchitis, bronchiolitis, and
tuberculosis. Allergic conditions, such as allergic rhinitis (hay fever) and
allergic asthma, involve an immune response to allergens like pollen, dust
mites, and animal danger. These conditions can lead to respiratory symptoms
like sneezing, runny nose, and wheezing. Exposure to harmful substances in the
workplace or environment can lead to respiratory diseases. Examples include
asbestos-related lung diseases, coal worker's pneumoconiosis (black lung
disease), and occupational asthma.
The global aging population is at a higher risk of
respiratory diseases. As the elderly population grows, there is a greater need
for vaccines to protect this vulnerable group. Government and healthcare
organizations worldwide recommend or mandate vaccinations for certain
respiratory diseases, such as influenza. These recommendations drive vaccine
adoption and coverage rates. The emergence of new respiratory viruses, as
witnessed during the COVID-19 pandemic, highlights the importance of
preparedness through vaccination. Governments and organizations invest in
vaccines as a key part of pandemic response plans. Public health campaigns and
initiatives promote vaccination and raise awareness about the benefits of
respiratory disease vaccines. These efforts aim to increase vaccine uptake. International
organizations like the World Health Organization (WHO) and UNICEF work to
expand vaccination access in low- and middle-income countries. Global
immunization programs aim to reduce the burden of respiratory diseases.
Key Market Drivers
Increasing Prevalence of Respiratory Diseases
The increasing prevalence of respiratory diseases plays a pivotal role in driving the growth of the Global Respiratory Disease Vaccine Market by creating a sustained demand for preventive healthcare solutions. Respiratory diseases represent a significant global health challenge. Current estimates show that 235 million people are affected by asthma, over 200 million individuals suffer from chronic obstructive pulmonary disease (COPD), and 65 million endure moderate-to-severe COPD. Furthermore, between 1–6% of the adult population, equating to more than 100 million people, experience sleep-disordered breathing. Annually, 8.7 million people develop tuberculosis (TB), while millions contend with pulmonary hypertension. Additionally, more than 50 million individuals are impacted by occupational lung diseases. Collectively, over 1 billion people globally are living with chronic respiratory conditions. This demand is shaped by several interconnected factors, including the rising incidence of respiratory conditions, their economic and healthcare system burden, and the growing public awareness of vaccination as a key preventive strategy.
The growing global burden of respiratory diseases is one of the primary factors driving the market for respiratory disease vaccines. Healthcare expenditures for respiratory diseases are placing an escalating financial strain on economies worldwide. In the United States alone, the annual economic burden of asthma is estimated at USD18 billion. This trend reflects the growing cost of managing respiratory conditions, further highlighting the urgent need for effective prevention and treatment strategies. Diseases such as influenza, pneumonia, chronic obstructive pulmonary disease (COPD), and respiratory syncytial virus (RSV) infections are increasingly common, particularly in vulnerable populations like the elderly and individuals with underlying health conditions. The rise in these conditions directly translates to a heightened demand for vaccines aimed at preventing or reducing the severity of these diseases. The seasonal nature of influenza outbreaks, which can lead to widespread illness, hospitalizations, and even death, results in consistent demand for influenza vaccines annually. With pneumonia being one of the leading causes of death worldwide, especially among the elderly, vaccination campaigns targeting pneumonia have gained prominence. Chronic obstructive pulmonary disease (COPD) ranks as the fourth leading cause of death globally, with incidence rates continuing to rise. Lung cancer, the most prevalent fatal cancer worldwide, claims the lives of over 1.4 million individuals annually, and its mortality rate is also on the rise. Respiratory infections caused by influenza result in 250,000 to 500,000 deaths each year, while also imposing an economic burden of approximately 71 to 167 billion US dollars annually. As the prevalence of chronic respiratory diseases like COPD rises, particularly due to smoking and environmental factors, the need for vaccines to prevent infections that exacerbate such conditions grows. Infections caused by RSV are significant among infants and the elderly, driving demand for vaccines that can protect these high-risk groups. The increasing prevalence of respiratory diseases places a significant burden on healthcare systems worldwide. Hospitalizations, long-term care, and the overall costs associated with treating respiratory conditions create a financial and operational strain on public health systems. In response, governments and healthcare organizations are focusing on prevention strategies, with vaccination being a key pillar of this approach. Vaccines reduce the incidence of severe disease and hospital admissions, thereby alleviating pressure on healthcare facilities and reducing treatment costs. This economic incentive pushes both public and private healthcare stakeholders to invest in and promote respiratory disease vaccines as a primary solution.
Respiratory diseases tend to follow seasonal patterns, such as the annual flu season, leading to periodic surges in cases. The continuous nature of these outbreaks, exacerbated by factors like climate change and the movement of populations, means that the demand for vaccines is consistently high. Governments and organizations, particularly in countries with temperate climates, invest heavily in seasonal vaccination programs to control outbreaks and prevent large-scale public health crises. Moreover, endemic outbreaks of diseases like RSV in certain regions also spur local and international vaccination efforts. The need for vaccines to control such outbreaks and prevent the spread of infections in communities drives market growth. The increasing prevalence of respiratory diseases is closely linked to the aging global population. Older adults are more susceptible to respiratory infections and often experience more severe outcomes, including hospitalization or death. This demographic shift amplifies the demand for vaccines designed to protect against common respiratory pathogens, particularly influenza and pneumonia. With aging populations in regions such as Europe, North America, and parts of Asia, governments are increasingly focused on improving vaccination coverage in this high-risk group. This has led to an uptick in both the volume of vaccines administered and the types of vaccines available, including those targeted specifically at the elderly.
The rising prevalence of respiratory diseases results in significant indirect costs, including lost productivity due to illness, premature mortality, and long-term disability. As respiratory diseases become more widespread, these economic burdens grow, encouraging governments and organizations to invest in preventive measures such as vaccination programs. The financial strain on businesses due to employee absenteeism or decreased productivity from sick workers further emphasizes the importance of respiratory disease prevention through vaccination. As businesses and insurance companies look to reduce the financial impact of respiratory diseases, they advocate for increased vaccination coverage among their employees and policyholders. With the growing awareness of the detrimental effects of respiratory diseases, particularly in light of the COVID-19 pandemic, there is a noticeable shift in public attitudes towards preventive healthcare. People are more inclined to seek out vaccines as a means to reduce the risk of respiratory infections. This trend, coupled with widespread education campaigns, boosts the demand for respiratory disease vaccines. Governments, healthcare organizations, and pharmaceutical companies actively promote vaccination as a cost-effective, long-term solution to managing the growing prevalence of respiratory diseases. The global trend toward healthier lifestyles and preventive measures further strengthens the market for vaccines.
Rising Aging Population
Elderly
individuals are more susceptible to respiratory diseases and complications. By 2030, one in six people globally will be aged 60 or older, with the number of individuals in this age group increasing from 1 billion in 2020 to 1.4 billion. By 2050, the global population of those aged 60 and above is projected to double to 2.1 billion. Additionally, the number of individuals aged 80 or older is expected to triple between 2020 and 2050, reaching 426 million. As
people age, their immune systems may weaken, making them more prone to
infections like influenza, pneumonia, and respiratory syncytial virus (RSV).
This increased vulnerability drives the need for vaccines to protect older
adults. Respiratory diseases can be more severe in older adults, leading to
higher hospitalization rates and mortality. Vaccines are essential for
preventing these severe outcomes in the elderly population. During influenza
and other respiratory disease outbreaks, the elderly are often at higher risk. Aging is the primary demographic risk factor for idiopathic pulmonary fibrosis (IPF). Similarly, the prevalence of chronic obstructive pulmonary disease (COPD) is reported to be two to three times higher among individuals over the age of 60. The ongoing global trend of an aging population is contributing significantly to the rising incidence of these respiratory diseases. Vaccinating this age group is crucial for epidemic control and reducing the
overall disease burden. Pneumococcal vaccines, which protect against pneumonia
and other infections caused by Streptococcus pneumoniae bacteria, are
recommended for older adults. These vaccines play a vital role in preventing
pneumococcal diseases.
Vaccinating the elderly is a public health strategy
to reduce the societal and economic impact of respiratory diseases. It helps in
lowering healthcare costs associated with disease treatment and
hospitalizations. By vaccinating older adults, it not only protects them but
also contributes to herd immunity. This indirectly benefits younger age groups
and individuals who may not be able to receive vaccines due to medical
contraindications. As life expectancy increases in many parts of the world, the
elderly population becomes a more significant proportion of the total
population. This demographic shift further underscores the importance of
vaccination to maintain health and quality of life in older age. The demand for
respiratory disease vaccines for the elderly population incentivizes
pharmaceutical companies to invest in research and development to create more
effective and targeted vaccines for this demographic. This factor will help in
the development of the Global Respiratory Disease Vaccine Market.
Vaccine Mandates and Recommendations
Some governments and institutions have implemented
vaccine mandates, requiring individuals to receive specific respiratory disease
vaccines. For example, healthcare workers may be required to receive annual
influenza vaccinations to reduce the risk of spreading the virus to vulnerable
patients. In many countries, children are required to receive certain
vaccinations before enrolling in schools or daycare centers. This includes
vaccines for diseases like measles, mumps, rubella, and sometimes influenza.
Such requirements ensure high vaccine coverage among school-age children. Some
countries may require proof of vaccination against certain respiratory
diseases, such as tuberculosis or COVID-19, for travelers or immigrants. These
requirements aim to prevent the spread of diseases across borders. Certain
professions, such as healthcare, may have vaccine mandates to protect both
workers and patients. For example, healthcare facilities may require employees
to receive vaccines against influenza, hepatitis B, or other respiratory
diseases. Government health agencies and organizations like the World Health
Organization (WHO) provide recommendations for vaccination against respiratory
diseases. These recommendations encourage healthcare providers to offer
vaccines to eligible individuals and the general population.
Health authorities often run public health
campaigns to promote vaccination against respiratory diseases, particularly
during flu seasons. These campaigns raise awareness about the importance of
vaccination and recommend vaccination to specific populations, such as pregnant
women and the elderly. During outbreaks or epidemics of respiratory diseases,
health authorities may recommend or mandate vaccination to control the spread
of the disease. For example, during the H1N1 influenza pandemic, vaccination
campaigns were widely promoted. Recommendations often target high-risk groups,
such as the elderly, young children, pregnant women, and individuals with
underlying health conditions. These individuals are more susceptible to severe
respiratory diseases, making vaccination crucial. Recommendations and mandates
can facilitate access to vaccines by making them readily available in
healthcare settings, including hospitals, clinics, and pharmacies. Encouraging
vaccination in the community helps achieve herd immunity, protecting those who
cannot be vaccinated due to medical reasons or contraindications. Health
authorities may use epidemiological data and research to make evidence-based
recommendations and mandates. These decisions are often informed by disease
prevalence and severity. This factor will pace up the demand of the Global
Respiratory Disease Vaccine Market.
Global Immunization Programs
Global immunization programs aim to ensure
equitable access to vaccines for people in low- and middle-income countries, as
well as underserved populations within high-income countries. This access
extends to respiratory disease vaccines, such as those for influenza and
pneumonia. These programs strive to achieve high vaccination coverage rates,
including coverage for respiratory diseases. The goal is to protect as many
individuals as possible against preventable respiratory infections. In response
to global health threats like pandemics (e.g., COVID-19), international organizations
and governments work to develop vaccination strategies and distribute vaccines
on a global scale. This preparedness includes respiratory disease vaccines for
pandemic control. By focusing on the prevention of respiratory diseases through
vaccination, global immunization programs aim to reduce the overall burden of
these diseases, including hospitalizations and mortality. Immunization programs
often include targeted campaigns for specific age groups, populations at higher
risk, and those in humanitarian settings. These campaigns raise awareness about
respiratory disease vaccines and encourage vaccination.
Global immunization efforts include strengthening
vaccine supply chains to ensure vaccines, including those for respiratory
diseases, reach even the most remote and resource-limited areas. Investment in
research and development of new and improved respiratory disease vaccines is
often a component of these programs. This fosters innovation and the
availability of more effective vaccines. Building the capacity of healthcare
systems and providers in vaccine administration and surveillance is part of
global immunization programs. This ensures the effective delivery of
respiratory disease vaccines. Collaborations between governments, international
organizations, and private-sector vaccine manufacturers are common in global
immunization programs. These partnerships enhance vaccine production,
affordability, and accessibility. Education and training initiatives are
integral to global immunization programs. They equip healthcare workers and
communities with knowledge about the importance of respiratory disease vaccination.
In times of crises, such as outbreaks or natural disasters, global immunization
programs can quickly mobilize resources and vaccines to protect vulnerable
populations from respiratory diseases. Robust monitoring and surveillance
systems are established to track vaccine coverage, adverse events, and disease
trends. Data collection informs program adjustments and vaccine distribution.
This factor will accelerate the demand of the Global Respiratory Disease
Vaccine Market.

Download Free Sample Report
Key Market Challenges
Vaccine Hesitancy and Misinformation
Vaccine hesitancy, characterized by reluctance or
refusal to receive vaccines, can lead to lower vaccination rates. When a
substantial portion of the population remains unvaccinated, it leaves
communities vulnerable to respiratory diseases, including influenza, pneumonia,
and COVID-19. Achieving herd immunity, where a sufficient percentage of the
population is immune to a disease, is crucial for protecting those who cannot
be vaccinated, such as individuals with medical contraindications. Vaccine
hesitancy can hinder efforts to reach herd immunity and indirectly impact
vulnerable individuals. When vaccination rates drop due to hesitancy, it can
lead to the resurgence of preventable respiratory diseases. Outbreaks of
vaccine-preventable diseases, like measles, have occurred in areas with low
vaccine coverage. Lower vaccination rates can result in increased disease
transmission and outbreaks, leading to public health crises. This places
additional strain on healthcare systems and resources. Misinformation and
disinformation about vaccines, often spread through social media and other
channels, can lead to false beliefs and fears about vaccine safety and
efficacy. This can erode public trust in vaccines and healthcare authorities. Concerns
about vaccine side effects, whether founded or unfounded, can contribute to
hesitancy. Misinformation can amplify fears and discourage vaccination. During
pandemics, like the COVID-19 pandemic, vaccine hesitancy can slow down efforts
to achieve widespread vaccination coverage, making it challenging to control
the spread of the virus and save lives. Persistent vaccine hesitancy can erode
public confidence in the entire vaccination process and the healthcare system.
This can have long-term repercussions for public health.
Supply Chain Disruptions
Disruptions in the supply chain, such as
interruptions in the availability of raw materials, can lead to delays in
vaccine production. This can result in vaccine shortages and affect the ability
to meet demand. Supply chain disruptions can affect the timely distribution of
vaccines to healthcare facilities, clinics, and pharmacies. This can lead to
logistical challenges and difficulties in ensuring that vaccines reach the
intended recipients. Supply chain disruptions can result in vaccines being
wasted if they cannot be stored or transported properly. Temperature-sensitive
vaccines, like some respiratory disease vaccines, are particularly vulnerable
to wastage if cold chain integrity is compromised. Interruptions in the supply
chain can impact the ability to provide vaccines to underserved regions,
especially in low- and middle-income countries. This can exacerbate global
health inequalities. During pandemics, like the COVID-19 pandemic, ensuring a
consistent and uninterrupted supply chain for vaccines is critical. Any
disruptions can slow down vaccination efforts and hinder the control of the
disease's spread. Supply chain disruptions can affect the capacity of vaccine
manufacturers to produce vaccines at scale. This can impact their ability to
meet the demand for respiratory disease vaccines. Shortages of key raw
materials, such as vials, adjuvants, and specialized equipment, can disrupt
vaccine production and lead to bottlenecks in the supply chain. Transportation
disruptions, including delays, restrictions, or interruptions in shipping and
logistics, can hinder the movement of vaccines across regions and countries.
Key Market Trends
Pneumococcal Vaccines
Pneumococcal diseases, including pneumonia and
invasive pneumococcal diseases (IPD), are associated with significant morbidity
and mortality worldwide. These diseases can affect people of all ages, but they
are particularly dangerous for young children and the elderly. Many countries
recommended pneumococcal vaccination for specific age groups, especially young
children, older adults, and individuals with certain underlying medical
conditions. These recommendations drove the demand for pneumococcal vaccines. Pneumonia
is a leading cause of morbidity and mortality, especially among children and
older adults. Pneumococcal vaccines are effective in preventing pneumonia,
making them a valuable tool in reducing the disease burden. Advances in vaccine
technology led to the development of pneumococcal conjugate vaccines, which
offer protection against a broader range of pneumococcal serotypes. These
vaccines have been increasingly adopted in vaccination programs. Pneumococcal
vaccination has shown a significant reduction in the incidence of pneumococcal
diseases, leading to improved public health outcomes and reduced healthcare
costs. Pneumococcal vaccines are part of pandemic preparedness efforts, as they
can help reduce the burden on healthcare systems during respiratory disease
outbreaks.
Segmental Insights
Type Insights
In 2024, the Global
Respiratory Disease Vaccine Market largest share was held by viral vaccine segment
and is predicted to continue expanding over the coming years. Viral respiratory
diseases, such as influenza (flu), respiratory syncytial virus (RSV), and
COVID-19, are widespread and have a significant impact on public health. These
diseases can cause a wide range of respiratory infections, from mild to severe,
and sometimes lead to hospitalizations and fatalities. This high prevalence
drives the demand for vaccines to prevent these viral infections. Vaccination
against viral respiratory diseases like influenza is a routine part of
healthcare in many countries. Seasonal flu vaccination campaigns are conducted annually
to protect individuals and prevent the spread of the virus, contributing to the
steady demand for viral vaccines. Viral respiratory diseases often
disproportionately affect elderly individuals and those with underlying health
conditions. Vaccination is recommended for these high-risk groups, further
driving demand for viral vaccines.
Distribution Channel Insights
In 2024, the Global Respiratory
Disease Vaccine Market largest share was held by hospital and retail pharmacies segment in the forecast
period and is predicted to continue expanding over the coming years. Hospitals and retail pharmacies are easily
accessible to the general population. Patients often visit hospitals for
routine check-ups, treatments, and vaccinations. Retail pharmacies, on the
other hand, are widely distributed in urban and rural areas, making them
convenient locations for vaccine administration. Healthcare providers,
including doctors and nurses, play a crucial role in recommending and
administering vaccines. Hospitals are primary healthcare settings where
patients receive recommendations for vaccination, and vaccines are administered
during hospital visits. Hospitals are frequently used as vaccination centres
during large-scale vaccination campaigns organized by governments and
healthcare organizations. For example, flu vaccination campaigns often involve
hospitals as key distribution points. Respiratory diseases are more common
among the elderly population. Many elderly individuals receive healthcare
services in hospitals, and hospitals are more likely to have specialized
departments for geriatric care, where vaccination is routinely offered.

Download Free Sample Report
Regional Insights
The Asia Pacific region held the largest market
share in the Global Respiratory Disease Vaccine Market in 2024. The Asia Pacific region is home to a substantial
portion of the world's population, including densely populated countries like
China and India. The sheer number of people in the region creates a significant
market for respiratory disease vaccines. Many countries in the Asia Pacific
have been experiencing economic growth, leading to increased healthcare
spending. This has allowed for greater investment in healthcare infrastructure,
including vaccination programs. Awareness about the importance of vaccination
has been on the rise in the Asia Pacific region. Governments and healthcare
organizations have been actively promoting immunization, including respiratory
disease vaccines, to combat the burden of preventable diseases. Like many other
regions, the Asia Pacific is experiencing demographic changes with a growing
aging population. Older adults are more susceptible to respiratory diseases,
such as influenza and pneumonia, driving the demand for vaccines.
Recent Developments
- In December 2024, A recent study in pigs demonstrates that inhaled vaccines could potentially reduce viral transmission and enhance efficiency, marking a significant advancement in the development of respiratory vaccines for human use. This research is a critical step toward optimizing vaccine delivery methods for broader human application.
- In October 2024, Pfizer Inc. that the U.S. Food and Drug Administration (FDA) has approved ABRYSVO® (Respiratory Syncytial Virus Vaccine), the company’s bivalent RSV prefusion F (RSVpreF) vaccine, for the prevention of lower respiratory tract disease (LRTD) caused by RSV in individuals aged 18 to 59 who are at increased risk for LRTD due to RSV. ABRYSVO now provides the broadest RSV vaccine indication for adults, expanding beyond the previously approved group of those aged 60 and older. Additionally, it remains the only RSV vaccine approved for use in pregnant individuals between 32 and 36 weeks of gestation, providing protection for infants from birth through 6 months of age.
- In October 2024, AstraZeneca will present new data from its Vaccines & Immune Therapies portfolio at the 13th annual IDWeek in Los Angeles, California, from October 16-19, 2024. The company will showcase advancements in the development of innovative vaccines targeting infectious diseases with high unmet medical needs, along with real-world evidence highlighting the impact of respiratory viral infections and the ongoing demand for effective protection.
- In October 2024, Pfizer Inc. will showcase data from its infectious disease portfolio at the IDWeek 2024 congress, taking place in Los Angeles from October 16-19, 2024. The company will present findings from 49 abstracts, derived from both Pfizer- and collaborator-led studies, emphasizing the company's progress in advancing the prevention and treatment of infectious diseases.
- In March 2024, Moderna, Inc. provided updates at its fifth Vaccines Day event, showcasing the progression and acceleration of its mRNA pipeline. The company highlighted clinical advancements, including data from its respiratory and latent vaccine portfolios, along with key announcements regarding commercial, manufacturing, and financial developments within its vaccines business.
- In May 2023, Pfizer Inc.
has announced that the U.S. Food and Drug Administration (FDA) has granted
approval for ABRYSVO™ (Respiratory Syncytial Virus Vaccine), Pfizer's bivalent
RSV prefusion F (RSVpreF) vaccine, intended for the prevention of lower
respiratory tract disease caused by RSV in individuals aged 60 and above.
ABRYSVO is an unadjuvanted vaccine comprising two preF proteins carefully
chosen to optimize protection against both RSV A and B strains, demonstrating
safety and efficacy. The FDA's decision is rooted in data obtained from the
pivotal Phase 3 clinical trial (NCT05035212) known as RENOIR (RSV vaccine
Efficacy study iNOlder adults Immunized against RSV disease). RENOIR is a
globally conducted, randomized, double-blind, and placebo-controlled study
aimed at evaluating the vaccine's effectiveness, immunogenicity, and safety
when administered as a single dose to adults aged 60 and older.
- In May 2023, The U.S. Food
and Drug Administration (FDA) has granted approval for Arexvy, marking it as
the first vaccine for respiratory syncytial virus (RSV) to be authorized for
use in the United States. Arexvy's approval is specifically for the prevention
of lower respiratory tract disease (LRTD) caused by RSV among individuals aged
60 years and older. RSV is a highly contagious virus responsible for lung and
respiratory infections across all age groups. Typically, RSV exhibits seasonal
circulation, commencing in the fall and reaching its peak during the winter
months. In older adults, RSV stands as a frequent cause of lower respiratory
tract disease (LRTD), characterized by lung-related issues, including
potentially life-threatening conditions such as pneumonia and bronchiolitis,
involving the inflammation of small airway passages in the lungs.
- In July 2023, AstraZeneca
and Sanofi have received approval in the United States for Beyfortus
(nirsevimab), which is designed for the prevention of lower respiratory tract
disease (LRTD) caused by respiratory syncytial virus (RSV). This approval
applies to newborns and infants who are either born during or entering their
initial RSV season, as well as children up to 24 months old who remain
susceptible to severe RSV disease during their second RSV season. Beyfortus
represents the first preventive option approved to safeguard a wide range of
infants, including those born at full term, preterm, or those with specific
health conditions that render them at risk for severe RSV disease. The vaccine
can be administered as a single dose, offering flexibility for administration
at the outset of the RSV season or shortly after birth for infants born during
the RSV season.
Key Market Players
- GSK plc.
- Johnson & Johnson
Services, Inc.
- Pfizer Inc.
- Sanofi SA
- Serum Institute of India
Pvt. Ltd.
- SINOVAC Biotech Ltd.
- Bavarian Nordic A/S
- Merck & Co., Inc.
- AstraZeneca Plc.
- Moderna Inc.
By
Type
|
By
Infection
|
By
Distribution Channel
|
By
Region
|
- Viral
Vaccine
- Bacterial
Vaccine
- Combination
Vaccine
|
- COVID-19
- Influenza
- Respiratory
Syncytial Virus (RSV)
- Pneumonia
- Others
|
- Hospital
& Retail Pharmacies
- Government
Suppliers
- Others
|
- North
America
- Europe
- Asia
Pacific
- South
America
- Middle
East & Africa
|
Report Scope:
In this report, the Global Respiratory Disease
Vaccine Market has been segmented into the following categories, in addition to
the industry trends which have also been detailed below:
- Respiratory
Disease Vaccine Market, By
Type:
o Viral Vaccine
o Bacterial Vaccine
o Combination Vaccine
- Respiratory
Disease Vaccine Market, By
Infection:
o COVID-19
o Influenza
o Respiratory Syncytial Virus (RSV)
o Pneumonia
o Others
- Respiratory
Disease Vaccine Market, By Distribution Channel:
o Hospital & Retail Pharmacies
o Government Suppliers
o Others
- Respiratory Disease Vaccine Market, By region:
o North America
§
United
States
§
Canada
§
Mexico
o
Asia-Pacific
§ China
§ India
§ South Korea
§ Australia
§ Japan
o
Europe
§
Germany
§
France
§
United
Kingdom
§
Spain
§
Italy
o
South
America
§
Brazil
§
Argentina
§
Colombia
o
Middle
East & Africa
§
South
Africa
§
Saudi
Arabia
§
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Respiratory
Disease Vaccine Market.
Available Customizations:
Global Respiratory Disease Vaccine Market report
with the given market data, Tech Sci Research offers customizations according
to a company's specific needs. The following customization options are
available for the report:
Company Information
- Detailed analysis and profiling of additional
market players (up to five).
Global Respiratory Disease Vaccine Market is an
upcoming report to be released soon. If you wish an early delivery of this
report or want to confirm the date of release, please contact us at [email protected]